Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer

Horn, Leora; Wang, Ziping; Wu, Gang; Poddubskaya, Elena; Mok, Tony; Reck, Martin; A. Wakelee, Heather; Chiappori, Alberto; Hyeong Lee, Ki; В. Бредер, В.; Orlov, Sergey; Çiçin, İrfan; Cheng, Ying; Liu, Yunpeng; Fan, Yun; G. Whisenant, Jennifer; Zhou, Yi; Oertel, V.; Harrow, Kim; Liang, Chris; Mao, Li; Selvaggi, Giovanni; Wu, Yi‐Long

doi:10.1001/jamaoncol.2021.3523

Public

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer

Published in JAMA Oncology • Sep 2, 2021

Authors:

Leora Horn

Ziping Wang

Gang Wu

Abstract

IMPORTANCE: Ensartinib, an oral tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system efficacy for patients with ALK-positive non-small cell lung cancer (NSCLC). OBJECTIVE: To compare ensartinib with crizotinib among patients with advanced ALK-p...

Subject

Crizotinib

Medicine

Anaplastic lymphoma kinase

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!